Abstract:

Objective To study the clinical efficacy and safety of disitamab vedotin （RC48） in the third-line and above third-line treatment of advanced gastric cancer. Methods The clinical data of 30 patients with advanced gastric cancer who had previously failed to receive at least two systemic chemotherapy regimens from August 2020 to August 2022 in Nantong Tumor Hospital were retrospectively analyzed. According to different treatment regimens， they were divided into RC48 group （n = 15） and control group （chemotherapy/targeted/immune monotherapy） （n = 15）. The objective response rate （ORR）， disease control rate （DCR）， progression-free survival （PFS）， overall survival （OS） and treatment-related adverse reactions were observed in the two groups. Results The median follow-up time was 7.5 months. The ORR of RC48 group and control group was 20% vs. 0% （P = 0.224）， DCR was 53.3% vs. 20% （P = 0.128）， mPFS was 4 months vs. 3 months （P = 0.479）， mOS was 18 months vs. 5 months （P = 0.043）. In terms of safety， the most common adverse reactions in the RC48 group and the control group were leukopenia and neutropenia.The overall incidence of adverse reactions in the two groups was comparable， and there were no fatal adverse events. Conclusion RC48 has a certain effect in the third-line and above third-line treatment of advanced gastric cancer， and patients are well tolerated.

Key words: disitamab vedotin, antibody-drug conjugate, human epidermal growth factor 2, gastric cancer